Toggle navigation
Home
Search
Services
Blog
Contact
About
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
University of California Irvine
Search grants from University of California Irvine
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Publications
Comments
Recent in Grantomics:
Fred Hutchinson Cancer Research Center
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Training in Critical Care Health Policy Research
Comparative and Evolutionary Biology of Hearing
Impact of Mid-Gut Bacteria on Anopheles Mosquitoes
Interstitial Cystitis Data Collection Program
Peptides and Reproduction
Recently added grants:
Intravascular Immune Surveillance by Anti-viral T Cells
Artificial intelligence Optical Coherence Tomography Guided Deep Anterior Lamellar Keratoplasty (AUTO-DALK)
Intermittent hypoxia and hypertension: Role of the lamina terminalis
Inside-out construction of the biliary system
Genomic biomarkers of splenic lymphoma
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CA075019-006
Application #
6828778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
2003
Total Cost
Indirect Cost
Institution
Name
University of California Irvine
Department
Type
DUNS #
City
State
Country
Zip Code
Related projects
NIH 2003
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
NIH 2002
N01 CA
Phase II Clinical Trial of Dfmo and Nsaidin Colon - Workstatement 45-261975019
/ University of California Irvine
Publications
Beeram, M; Tan, Q-T N; Tekmal, R R et al.
(2007)
Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling.
Ann Oncol 18:1323-8
Comments
Be the first to comment on this grant